Anzeige
Mehr »
Login
Sonntag, 05.05.2024 Börsentäglich über 12.000 News von 685 internationalen Medien
Cannabisaktien sollten nun den S&P um 60% outperformen!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
22 Leser
Artikel bewerten:
(0)

Global Central Nervous System (CNS) Biomarkers Market 2016-2022 - Market is Expected to Reach Up to $6.2 Billion by 2022 Growing at 10.4% CAGR - Research and Markets

DUBLIN, June 10, 2016 /PRNewswire/ --

Research and Markets has announced the addition of the "Global Central Nervous System (CNS) Biomarkers Market Insights, Opportunity, Analysis, Market Shares And Forecast 2016 - 2022" report to their offering.

The global CNS biomarker market is expected to reach up to $6.2 billion by 2022 growing at 10.4% CAGR during 2016-2022.

The demand for CNS biomarker has increased with the development of in proteomics, genomics and imaging system, which is a major drivers of the Global Central Nervous System Biomarkers Market. The global CNS biomarker market is witnessing a moderate to high growth in the recent years and is expected to continue so on in the near future.

The major factors identified that are driving the CNS biomarker market are support from private players and government for increased research and development, development of genomics and imaging system, rapidly increasing aging population and increased public private partnerships.

Recently, FDA has approved use CNS biomarkers which has led to its significant growth in the North American region. The world is experiencing a significant growth in aging population. As per Administration for Community Living, population aged 65 and above is estimated to reach more than 80 million by 2050, which is twice of that estimated in 2012.

Key Topics Covered:

1. Introduction

2. Market Overview

3. Market Determinants

4. Market Segmentation

5. Geographical Analysis

6. Company Profiling: - (Over, Scot Analysis, Strategic Review)

- Abastar Mdx Inc

- Abiant Inc

- Acumen Pharmaceuticals Inc

- Adlyfe Inc

- Alseres Pharmaceuticals Inc

- Apitope International

- Aposense

- Applied Neurosolutions Inc

- Avacta Group Plc

- Avid Radiopharmaceuticals Inc

- Banyan Biomarkers

- Diagenic Asa

- Ekfdiagnostics Holdings Inc

- Enzo Biochem Inc

- Exonhit Therapeutics

- Genenews Ltd

- Glycominds Ltd

- Great Lakes Neurotechnologies

- Innogenetics Biologicals

- Innovative Neurotechnologies Inc

- Merc & Co. In

- Metabolon Inc

- Myriad Rbm Inc

- Oligomerix Inc

- Opko Health Inc

- Osta Biotechnologies Inc

- Proteome Sciences Products

- Psynova Neurotech Ltd

- Ridge Diagnostics

- Sabiosciences

- Satori Pharmaceutical Inc

- Thermo Fisher Scientific

For more information visit http://www.researchandmarkets.com/research/fpj7lb/global_central

Media Contact:

Research and Markets

Laura Wood, Senior Manager

press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470

For U.S./CAN Toll Free Call +1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907

Fax (outside U.S.): +353-1-481-1716

Kupfer - Jetzt! So gelingt der Einstieg in den Rohstoff-Trend!
In diesem kostenfreien Report schaut sich Carsten Stork den Kupfer-Trend im Detail an und gibt konkrete Produkte zum Einstieg an die Hand.
Hier klicken
© 2016 PR Newswire
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.